JP2011513399A - 同種癌細胞による免疫療法 - Google Patents
同種癌細胞による免疫療法 Download PDFInfo
- Publication number
- JP2011513399A JP2011513399A JP2010549646A JP2010549646A JP2011513399A JP 2011513399 A JP2011513399 A JP 2011513399A JP 2010549646 A JP2010549646 A JP 2010549646A JP 2010549646 A JP2010549646 A JP 2010549646A JP 2011513399 A JP2011513399 A JP 2011513399A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cancer cells
- subject
- allogeneic
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 173
- 201000011510 cancer Diseases 0.000 title claims abstract description 77
- 230000000735 allogeneic effect Effects 0.000 title claims abstract description 41
- 238000009169 immunotherapy Methods 0.000 title claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims abstract description 147
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 46
- 230000003053 immunization Effects 0.000 claims abstract description 45
- 238000002649 immunization Methods 0.000 claims abstract description 44
- 238000002255 vaccination Methods 0.000 claims abstract description 38
- 230000002163 immunogen Effects 0.000 claims abstract description 27
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims abstract description 24
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 18
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 11
- 230000014759 maintenance of location Effects 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 241000701822 Bovine papillomavirus Species 0.000 claims description 5
- 230000000779 depleting effect Effects 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 28
- 108091007433 antigens Proteins 0.000 abstract description 28
- 102000036639 antigens Human genes 0.000 abstract description 28
- 230000003248 secreting effect Effects 0.000 abstract description 7
- 230000028993 immune response Effects 0.000 abstract description 4
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 49
- 230000035755 proliferation Effects 0.000 description 30
- 229960005486 vaccine Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 108010058846 Ovalbumin Proteins 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 229940092253 ovalbumin Drugs 0.000 description 11
- 210000003200 peritoneal cavity Anatomy 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000006698 induction Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 230000002950 deficient Effects 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 230000007115 recruitment Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 206010062016 Immunosuppression Diseases 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 5
- 230000005809 anti-tumor immunity Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000006041 cell recruitment Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004479 myeloid suppressor cell Anatomy 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 201000008162 B cell deficiency Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101001123526 Ambrosia artemisiifolia Pectate lyase 4 Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004460 liquid liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3342508P | 2008-03-03 | 2008-03-03 | |
| PCT/US2009/001330 WO2009114085A2 (en) | 2008-03-03 | 2009-03-03 | Allogeneic cancer cell-based immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138932A Division JP2014208690A (ja) | 2008-03-03 | 2014-07-04 | 同種癌細胞による免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011513399A true JP2011513399A (ja) | 2011-04-28 |
| JP2011513399A5 JP2011513399A5 (enExample) | 2012-01-12 |
Family
ID=41065702
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010549646A Pending JP2011513399A (ja) | 2008-03-03 | 2009-03-03 | 同種癌細胞による免疫療法 |
| JP2014138932A Pending JP2014208690A (ja) | 2008-03-03 | 2014-07-04 | 同種癌細胞による免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138932A Pending JP2014208690A (ja) | 2008-03-03 | 2014-07-04 | 同種癌細胞による免疫療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8475785B2 (enExample) |
| EP (2) | EP2752193B1 (enExample) |
| JP (2) | JP2011513399A (enExample) |
| KR (1) | KR20110009095A (enExample) |
| CN (1) | CN102014937A (enExample) |
| AU (1) | AU2009223838B2 (enExample) |
| CA (1) | CA2717854C (enExample) |
| DK (1) | DK2257301T3 (enExample) |
| ES (1) | ES2460899T3 (enExample) |
| IL (1) | IL207958A (enExample) |
| WO (1) | WO2009114085A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018509888A (ja) * | 2015-02-06 | 2018-04-12 | ヒート バイオロジクス，インコーポレイテッド | ワクチンおよび共刺激分子を共発現するベクター |
| WO2018199318A1 (ja) * | 2017-04-28 | 2018-11-01 | 国立大学法人高知大学 | 抗ｇｐｃ－１抗体 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1054683B1 (en) * | 1998-02-20 | 2007-04-11 | University Of Miami | Modified heat shock protein-antigenic peptide complex |
| EP2752193B1 (en) | 2008-03-03 | 2017-01-11 | The University of Miami | Allogeneic cancer cell-based immunotherapy |
| WO2009117116A2 (en) | 2008-03-20 | 2009-09-24 | University Of Miami | Heat shock protein gp96 vaccination and methods of using same |
| US20110223196A1 (en) * | 2008-11-21 | 2011-09-15 | University Of Miami | Hiv/siv vaccines for the generation of mucosal and systemic immunity |
| EP2571522A4 (en) * | 2010-05-21 | 2013-11-20 | Univ Miami | CANCER TREATMENT |
| JP6385280B2 (ja) * | 2012-01-20 | 2018-09-05 | トーメ クロイツ、フェルナンド | 自家癌細胞ワクチン |
| WO2015131176A1 (en) * | 2014-02-28 | 2015-09-03 | Podack Eckhard R | Compositions, methods, and kits for treatment of cancer |
| CA3040123A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
| US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
| DE102021124078A1 (de) | 2021-09-17 | 2023-03-23 | Timm Golüke | Kosmetikzusammensetzung zur Anwendung auf der Haut |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996010411A1 (en) * | 1994-09-30 | 1996-04-11 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
| WO1997010001A1 (en) * | 1995-09-13 | 1997-03-20 | Fordham University | Treatment or prevention of neoplastic and infectious diseases with heat shock/stress proteins |
| JP2002506005A (ja) * | 1998-02-20 | 2002-02-26 | ユニバーシティー オブ マイアミ | 改変型熱ショックタンパク質−抗原性ペプチド複合体 |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5217891A (en) | 1987-07-28 | 1993-06-08 | Chiron Corporation | DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides |
| DE68924162T2 (de) | 1988-06-15 | 1996-04-25 | Medical Res Council | Stressproteine und verwendungen dafür. |
| US5137819A (en) | 1988-07-08 | 1992-08-11 | University Of British Columbia | Cellulose binding fusion proteins for immobilization and purification of polypeptides |
| WO1990002564A1 (en) | 1988-09-12 | 1990-03-22 | Codon | Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi |
| US5232833A (en) | 1988-09-14 | 1993-08-03 | Stressgen Biotechnologies Corporation | Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| EP0773294A3 (en) | 1989-07-28 | 1997-09-17 | Us Health | Powerful system for targeted genetic cloning |
| GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
| US5348945A (en) | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
| US5188964A (en) | 1990-04-12 | 1993-02-23 | Board Of Regents, The University Of Texas System | Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination |
| GB9016315D0 (en) | 1990-07-25 | 1990-09-12 | Burnie James P | Medicaments |
| DE69126668T2 (de) | 1990-11-08 | 1997-10-23 | University College London, London | Mycobacterium als adjuvans für antigene |
| GB9024320D0 (en) | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
| GB2251186A (en) | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
| AU643141B2 (en) | 1991-03-15 | 1993-11-04 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| GB9200949D0 (en) | 1992-01-17 | 1992-03-11 | Medical Res Council | Diagnostic peptides |
| FR2688227A1 (fr) | 1992-03-04 | 1993-09-10 | Inst Nat Sante Rech Med | Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| EP0630404A1 (en) | 1992-03-09 | 1994-12-28 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale | Protein compound capable of inhibiting tumoral growth |
| EP0636248A4 (en) | 1992-04-14 | 1996-11-13 | Univ Duke | METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS. |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| GB2270076A (en) | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
| GB9223816D0 (en) | 1992-11-13 | 1993-01-06 | Medical Res Council | Heat shock proteins and the treatment of tumours |
| CA2158655A1 (en) | 1993-03-19 | 1994-09-29 | Max L. Birnstiel | Process for preparing cancer vaccines |
| US5496934A (en) | 1993-04-14 | 1996-03-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acids encoding a cellulose binding domain |
| US5645829A (en) | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| WO1995004824A1 (en) | 1993-08-05 | 1995-02-16 | Medvet Science Pty. Ltd. | Generation of dna libraries and retroviral vectors for same |
| US5705159A (en) | 1993-08-31 | 1998-01-06 | John Wayne Cancer Institute | Immunoreactive peptide sequence from a 43 KD human cancer antigen |
| US5444087A (en) | 1993-10-19 | 1995-08-22 | Bristol-Myers Squibb Company | Manumycin compounds |
| US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
| WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| ATE172099T1 (de) | 1994-07-08 | 1998-10-15 | Baxter Int | Implantierte vorrichtung mit tumorzellen zur behandlung von krebs |
| US5772995A (en) | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
| DK0784483T3 (da) | 1994-10-03 | 2001-03-26 | Us Gov Health & Human Serv | Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US6331299B1 (en) | 1995-08-18 | 2001-12-18 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious disease and compositions useful in same |
| US6719974B1 (en) | 1995-08-18 | 2004-04-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
| US6761892B1 (en) | 1995-08-18 | 2004-07-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
| CA2229543A1 (en) | 1995-08-18 | 1997-02-27 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
| US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| US5985270A (en) | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
| JPH11513369A (ja) | 1995-09-13 | 1999-11-16 | フォーダム ユニバーシティー | 熱ショックタンパク質を用いる治療及び予防方法 |
| DE19602985A1 (de) | 1996-01-27 | 1997-07-31 | Max Delbrueck Centrum | Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren |
| WO1997026910A2 (de) | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
| BR9708387A (pt) | 1996-03-28 | 2000-01-04 | Genitrix Llc | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. |
| US5747332A (en) | 1996-09-20 | 1998-05-05 | University Of New Mexico | Methods for purifying and synthesizing heat shock protein complexes |
| US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
| EP0941315B1 (en) | 1996-11-26 | 2006-03-01 | Stressgen Biotechnologies Corporation | Fusion proteins containing stress proteins for inducing immune responses |
| EP1012274B2 (en) | 1997-01-28 | 2011-06-15 | Human Genome Sciences, Inc. | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l) |
| US8329179B2 (en) | 1997-01-28 | 2012-12-11 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
| US7452538B2 (en) | 1997-01-28 | 2008-11-18 | Human Genome Sciences, Inc. | Death domain containing receptor 4 antibodies and methods |
| US5830464A (en) | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
| US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| US20040136951A1 (en) | 1997-03-17 | 2004-07-15 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US20050233958A1 (en) | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
| US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| US8101349B2 (en) | 1997-12-23 | 2012-01-24 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells and their methods of use II |
| ES2328194T3 (es) | 1998-05-26 | 2009-11-10 | Genitrix Llc | Composiciones y procedimientos de modulacion de una respuesta inmunitaria frente a un antigeno mediante la administracion de celulas recubiertas con citocina. |
| US6451316B1 (en) | 1998-10-05 | 2002-09-17 | University Of Conneticut Health Center | Methods for generating antigen-reactive T cells in vitro |
| US6797480B1 (en) | 1998-10-05 | 2004-09-28 | University Of Connecticut Health Center | Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents |
| US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
| WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
| US6317435B1 (en) | 1999-03-08 | 2001-11-13 | Qualcomm Incorporated | Method and apparatus for maximizing the use of available capacity in a communication system |
| HK1046635B (en) | 1999-06-09 | 2009-10-09 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
| WO2009118248A2 (en) | 2008-03-26 | 2009-10-01 | Clariant International Ltd | Improved optical brightening compositions |
| EP1284986A4 (en) | 2000-04-17 | 2005-08-24 | James E Rothman | COMPLEXIZING PROTEIN ANTIGENES AND HEAT SHOCK PROTEINS BY JAVELIN |
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| SK18362002A3 (sk) | 2000-06-26 | 2004-02-03 | Stressgen Biotechnologies Corporation | Použitie prostriedku s obsahom fúzneho proteínu |
| WO2002012281A2 (en) | 2000-08-03 | 2002-02-14 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
| US7132109B1 (en) | 2000-10-20 | 2006-11-07 | University Of Connecticut Health Center | Using heat shock proteins to increase immune response |
| US20070292411A1 (en) | 2000-11-08 | 2007-12-20 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| US20060062786A1 (en) | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| WO2004016753A2 (en) | 2002-08-15 | 2004-02-26 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US20050129616A1 (en) | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US20050214209A1 (en) | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20050214210A1 (en) | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| WO2003005964A2 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US20050019752A1 (en) | 2001-11-16 | 2005-01-27 | Genoveffa Franchini | Novel chimeric rev, tat, and nef antigens |
| US7955845B2 (en) | 2001-11-20 | 2011-06-07 | Dana Farber Cancer Institute, Inc. | Modified antigen-presenting cells |
| US20050214206A1 (en) | 2001-12-20 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20050214207A1 (en) | 2001-12-20 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind toTRAIL receptors |
| US20050214208A1 (en) | 2001-12-20 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20050214205A1 (en) | 2001-12-20 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| EP1539197A4 (en) * | 2002-02-01 | 2006-08-02 | Univ Jefferson | TREATMENT OF TUMOR CELLS FOR USE IN IMMUNOTHERAPY IN CANCER |
| KR20040105736A (ko) | 2002-02-28 | 2004-12-16 | 안티제닉스 아이엔씨 | 스트레스 단백질의 올리고머화에 기초한 방법 및 산물 |
| US6984389B2 (en) | 2002-04-25 | 2006-01-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| RU2376029C2 (ru) | 2002-04-25 | 2009-12-20 | Юниверсити Оф Коннектикут Хелт Сентер | Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия |
| AU2003234469A1 (en) | 2002-05-02 | 2003-11-17 | University Of Connecticut Health Center | Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| US20070298041A1 (en) | 2002-06-28 | 2007-12-27 | Tomlinson Ian M | Ligands That Enhance Endogenous Compounds |
| US20040091503A1 (en) | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| BR0313650A (pt) | 2002-08-20 | 2007-08-14 | Genitrix Llc | composição, vetor de expressão, composição de vacina e uso |
| US7629440B2 (en) | 2002-08-20 | 2009-12-08 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| CN104911210A (zh) | 2002-10-09 | 2015-09-16 | 衣阿华中央卫生系统 | 使用表达α(1,3)-半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫 |
| AU2003301526A1 (en) | 2002-10-25 | 2004-05-13 | University Of Connecticut Health Center | Immunotherapy of cancer through controlled cell lysis |
| JP2006514088A (ja) | 2003-02-20 | 2006-04-27 | ユニバーシティー オブ コネティカット ヘルス センター | 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法 |
| JP4976848B2 (ja) | 2003-02-20 | 2012-07-18 | ユニバーシティー オブ コネティカット ヘルス センター | アルファ（２）マクログロブリン−抗原分子複合体を用いる癌および感染性疾患の治療のための方法および組成物 |
| WO2004078921A2 (en) | 2003-02-27 | 2004-09-16 | University Of Connecticut Health Center | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
| KR20060026004A (ko) | 2003-02-28 | 2006-03-22 | 안티제닉스 아이엔씨 | 당단백질 및 항원성 분자의 올리고머화를 조장하는 렉틴의용도 |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| EP1633316A4 (en) | 2003-05-06 | 2008-04-02 | Human Genome Sciences Inc | ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS |
| KR100499278B1 (ko) * | 2003-07-05 | 2005-07-01 | 학교법인 포항공과대학교 | 로텍산 화합물이 공유결합된 고체 기판 및 이를 이용한바이오칩 |
| JP2007505147A (ja) | 2003-09-12 | 2007-03-08 | アンティジェニクス インコーポレーテッド | 単純ヘルペスウイルス感染の治療および予防用ワクチン |
| AU2004276522B2 (en) | 2003-09-26 | 2010-12-02 | Merck Serono Sa | Leader sequences for use in production of proteins |
| WO2005030136A2 (en) * | 2003-09-26 | 2005-04-07 | University Of Miami | Tumor vaccine |
| FR2867982B1 (fr) * | 2004-03-26 | 2007-07-20 | Jean Marie Andrieu | Procede pour amplifier l'activite de vaccins therapeutiques |
| RU2006140377A (ru) | 2004-04-16 | 2008-05-27 | Дженентек, Инк. (Us) | Способ усиления уничтожения в-клеток |
| WO2005120558A2 (en) | 2004-05-25 | 2005-12-22 | University Of Connecticut Health Center | Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| CA2943949C (en) | 2004-10-06 | 2020-03-31 | Mayo Foundation For Medical Education And Research | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer |
| CA2597511A1 (en) | 2005-02-24 | 2006-11-23 | Medical Research Council | Hivcon: an hiv immunogen and uses thereof |
| WO2007030571A2 (en) | 2005-09-06 | 2007-03-15 | Molecular Image Inc. | Identification of targets and development of reagents for testing and molecular imaging of human disease |
| CN101057975B (zh) | 2006-12-13 | 2012-10-10 | 中国科学院微生物研究所 | 一种抗免疫耐受性和免疫缺陷性病毒的鸡尾酒疫苗及其应用 |
| US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| US20080206235A1 (en) | 2006-12-27 | 2008-08-28 | Johns Hopkins University | Compositions and methods for stimulating an immune response |
| WO2009018500A1 (en) | 2007-07-31 | 2009-02-05 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| EP2752193B1 (en) | 2008-03-03 | 2017-01-11 | The University of Miami | Allogeneic cancer cell-based immunotherapy |
| WO2009117116A2 (en) | 2008-03-20 | 2009-09-24 | University Of Miami | Heat shock protein gp96 vaccination and methods of using same |
| IL190438A0 (en) | 2008-03-25 | 2008-12-29 | K M B Y Ltd | A method of setting a drill for drilling a hole in a bone coaxial to the hole in the nail and aiming device for realizing this method |
| CA2720173A1 (en) | 2008-04-02 | 2009-10-08 | Sanofi-Aventis | Highly bridged peptides from actinomadura namibiensis |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US20110223196A1 (en) | 2008-11-21 | 2011-09-15 | University Of Miami | Hiv/siv vaccines for the generation of mucosal and systemic immunity |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| EP2387415A1 (en) | 2009-01-16 | 2011-11-23 | AGIRx Limited | Vaccine compositions |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| RU2015117604A (ru) | 2009-04-03 | 2015-10-27 | Эйдженус Инк. | Способы получения и применения мультишаперон-антигенных комплексов |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| US9459246B2 (en) | 2009-09-08 | 2016-10-04 | Nodality, Inc. | Induced intercellular communication |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| WO2011069528A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Lyophilization of nucleic acids in lactate-containing solutions |
| IL323000A (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| WO2011131472A1 (en) | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| US8865653B2 (en) | 2010-04-22 | 2014-10-21 | Institut Gustave Roussy | Method of treatment for immunogenic treatment resistant cancer |
| EP2571522A4 (en) | 2010-05-21 | 2013-11-20 | Univ Miami | CANCER TREATMENT |
| KR20140045341A (ko) | 2011-02-23 | 2014-04-16 | 유니버시티 오브 마이애미 | Siv/hiv로부터의 보호를 위한 조합된 세포 기반의 gp96-ig-siv/hiv, 재조합 gp120 단백질 백신접종 |
| CA2874998A1 (en) | 2011-05-27 | 2012-12-06 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| JP6518199B6 (ja) | 2013-03-15 | 2019-06-12 | ノヴェロジックス・バイオテクノロジー，インコーポレーテッド | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
| US20160030659A1 (en) | 2013-03-15 | 2016-02-04 | Novelogics Biotechnology, Inc. | Methods and devices for removal of immunosuppressive ligands |
-
2009
- 2009-03-03 EP EP14152006.4A patent/EP2752193B1/en active Active
- 2009-03-03 US US12/921,151 patent/US8475785B2/en not_active Expired - Fee Related
- 2009-03-03 CA CA2717854A patent/CA2717854C/en active Active
- 2009-03-03 KR KR1020107022069A patent/KR20110009095A/ko not_active Ceased
- 2009-03-03 ES ES09720311.1T patent/ES2460899T3/es active Active
- 2009-03-03 AU AU2009223838A patent/AU2009223838B2/en not_active Ceased
- 2009-03-03 DK DK09720311.1T patent/DK2257301T3/da active
- 2009-03-03 JP JP2010549646A patent/JP2011513399A/ja active Pending
- 2009-03-03 WO PCT/US2009/001330 patent/WO2009114085A2/en not_active Ceased
- 2009-03-03 CN CN200980115985XA patent/CN102014937A/zh active Pending
- 2009-03-03 EP EP09720311.1A patent/EP2257301B1/en not_active Not-in-force
-
2010
- 2010-09-02 IL IL207958A patent/IL207958A/en active IP Right Grant
-
2013
- 2013-06-28 US US13/930,818 patent/US9238064B2/en active Active
-
2014
- 2014-07-04 JP JP2014138932A patent/JP2014208690A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996010411A1 (en) * | 1994-09-30 | 1996-04-11 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
| WO1997010001A1 (en) * | 1995-09-13 | 1997-03-20 | Fordham University | Treatment or prevention of neoplastic and infectious diseases with heat shock/stress proteins |
| JP2002506005A (ja) * | 1998-02-20 | 2002-02-26 | ユニバーシティー オブ マイアミ | 改変型熱ショックタンパク質−抗原性ペプチド複合体 |
Non-Patent Citations (5)
| Title |
|---|
| JPN6013018235; Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．１７９， Ｎｏ．４, 2007, ｐ．２３１０-２３１７ * |
| JPN6013018236; 山崎 浩一，外１２名: '分泌型ｇｐ９６融合蛋白質（ｇｐ９６-Ｉｇ）による免疫遺伝子療法の基礎的検討' 肺癌 第４１巻，第５号, 2001, ｐ．５２７ * |
| JPN6013018237; 山崎 浩一，外１２名: '分泌型ｇｐ９６融合蛋白質（ｇｐ９６-Ｉｇ）による癌拒絶と免疫遺伝子治療への応用' 肺癌 第４０巻，第５号, 2000, ｐ．３８８ * |
| JPN6013018238; 大泉 聡史，外１２名: 'Ｂ細胞の非存在下における腫瘍細胞産生型ｇｐ９６の抗腫瘍効果の検討' 肺癌 第４６巻，第５号, 2006, ｐ．５３６ * |
| JPN6013018239; Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．１６３， Ｎｏ．１０, 1999, ｐ．５１７８-５１８２ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018509888A (ja) * | 2015-02-06 | 2018-04-12 | ヒート バイオロジクス，インコーポレイテッド | ワクチンおよび共刺激分子を共発現するベクター |
| WO2018199318A1 (ja) * | 2017-04-28 | 2018-11-01 | 国立大学法人高知大学 | 抗ｇｐｃ－１抗体 |
| JPWO2018199318A1 (ja) * | 2017-04-28 | 2020-03-12 | 国立大学法人高知大学 | 抗ｇｐｃ−１抗体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2717854A1 (en) | 2009-09-17 |
| US20110250229A1 (en) | 2011-10-13 |
| CA2717854C (en) | 2019-02-19 |
| EP2257301A4 (en) | 2013-01-16 |
| EP2752193A1 (en) | 2014-07-09 |
| WO2009114085A2 (en) | 2009-09-17 |
| JP2014208690A (ja) | 2014-11-06 |
| US9238064B2 (en) | 2016-01-19 |
| KR20110009095A (ko) | 2011-01-27 |
| EP2257301B1 (en) | 2014-01-22 |
| EP2752193B1 (en) | 2017-01-11 |
| AU2009223838A1 (en) | 2009-09-17 |
| ES2460899T3 (es) | 2014-05-14 |
| US20130302376A1 (en) | 2013-11-14 |
| DK2257301T3 (da) | 2014-04-28 |
| IL207958A (en) | 2015-09-24 |
| WO2009114085A3 (en) | 2009-12-03 |
| IL207958A0 (en) | 2010-12-30 |
| EP2257301A2 (en) | 2010-12-08 |
| AU2009223838B2 (en) | 2012-07-26 |
| CN102014937A (zh) | 2011-04-13 |
| US8475785B2 (en) | 2013-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014208690A (ja) | 同種癌細胞による免疫療法 | |
| JP6074435B2 (ja) | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 | |
| Dunn‐Pirio et al. | Immunotherapy approaches in the treatment of malignant brain tumors | |
| Ochsenbein | Principles of tumor immunosurveillance and implications for immunotherapy | |
| Gerloni et al. | CD4 T cells in tumor immunity | |
| Loeser et al. | Spontaneous tumor rejection by cbl-b–deficient CD8+ T cells | |
| CA2786585C (en) | Methods and compositions for liquidation of tumors | |
| RU2448729C2 (ru) | Композиции, вызывающие специфический ответ цитотоксических т-лимфоцитов, включающие лимфо-аблативное соединение и молекулу, содержащую антигенные последовательности и нацеленную на специализированные антиген-презентирующие клетки | |
| CN102884194B (zh) | 含增强免疫应答的Fc融合蛋白的方法和组合物 | |
| CN106456730A (zh) | 用于诱导或延长细胞之细胞毒性免疫应答的方法的药物 | |
| Mocellin et al. | Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines | |
| JP2019500028A (ja) | 癌免疫療法で使用するための二重特異性ｔ細胞を製造する方法 | |
| Oizumi et al. | Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells | |
| Chung et al. | Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide | |
| Sanchez et al. | T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas | |
| Yi | Immunotherapy in multiple myeloma: current strategies and future prospects | |
| US20230036135A1 (en) | Bcg car constructs and methods of their manufacture and use | |
| JP2023500671A (ja) | がんのｔ細胞治療のための細胞傷害性エフェクターメモリーｔ細胞の産生方法 | |
| Garcia et al. | Cancer immunology and novel strategies for immunotherapy | |
| Berger et al. | Cancer immunotherapy: from promise to practice | |
| Veiga et al. | Lymphocytes transfectes pour therapie antitumorale | |
| Mukherjee et al. | Therapeutic Efficacy of Muci-Specific Cytotoxic T Lymphocytes and CD137 Co-Stimulation in a Spontaneous Mammary Cancer Model | |
| Olson et al. | Enhancing Anti-Tumor Activity Against Glioblastoma and Neuroblastoma by Retargeting T Cells with OKT3 X Anti-EGFR | |
| Addis et al. | Review on Immunotherapy Strategies against Infectious and Noninfectious Diseases | |
| Gajewski | Principles of Cancer Immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111114 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121031 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130723 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131022 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140704 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140901 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140919 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160119 |